科济药业控股有限公司（股票代码：02171，简称“科济药业-B”）于2026年8月6日披露2026年7月股份变动月报表。报告显示，截至2026年7月31日，公司授权股本未发生变化，仍为200,000,000,000股，面值每股USD 0.00000025，注册股本总额50,000美元。报告期内，公司已发行股份由上月底的594,675,998股减少至594,229,547股，同时库存股份由7,818,000股减少至0股，总股本相应从602,493,998股降至594,229,547股，减少8,264,451股。
根据披露，当月公司因首次公开发售后购股权计划行使新增发行7,000股，因2019年股权激励计划新增发行1,549股；同期公司于7月内先后购回455,000股并完成注销，同时注销7,818,000股库存股份，另有711,000股购回股份尚未注销。公司确认已符合相关公众持股量要求，并承诺遵守香港联交所《上市规则》及其他适用法律法规。上述月报由科济药业-B执行董事李宗海签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.